- Home
- ROIV vs CWAN Comparison
ROIV vs CWAN Comparison
Compare ROIV & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CWAN
- Stock Information
- Founded
- ROIV 2014
- CWAN 2004
- Country
- ROIV United Kingdom
- CWAN United States
- Employees
- ROIV N/A
- CWAN N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CWAN Computer Software: Prepackaged Software
- Sector
- ROIV Health Care
- CWAN Technology
- Exchange
- ROIV Nasdaq
- CWAN Nasdaq
- Market Cap
- ROIV 8.6B
- CWAN 5.8B
- IPO Year
- ROIV N/A
- CWAN 2021
- Fundamental
- Price
- ROIV $15.28
- CWAN $19.18
- Analyst Decision
- ROIV Strong Buy
- CWAN Buy
- Analyst Count
- ROIV 4
- CWAN 10
- Target Price
- ROIV $15.50
- CWAN $31.70
- AVG Volume (30 Days)
- ROIV 7.8M
- CWAN 4.0M
- Earning Date
- ROIV 11-11-2025
- CWAN 11-05-2025
- Dividend Yield
- ROIV N/A
- CWAN N/A
- EPS Growth
- ROIV N/A
- CWAN N/A
- EPS
- ROIV N/A
- CWAN 1.66
- Revenue
- ROIV $23,233,000.00
- CWAN $551,094,000.00
- Revenue This Year
- ROIV N/A
- CWAN $64.64
- Revenue Next Year
- ROIV $281.14
- CWAN $30.03
- P/E Ratio
- ROIV N/A
- CWAN $11.52
- Revenue Growth
- ROIV N/A
- CWAN 36.68
- 52 Week Low
- ROIV $8.73
- CWAN $17.98
- 52 Week High
- ROIV $16.05
- CWAN $35.71
- Technical
- Relative Strength Index (RSI)
- ROIV 82.00
- CWAN 38.51
- Support Level
- ROIV $13.81
- CWAN $19.04
- Resistance Level
- ROIV $14.48
- CWAN $20.59
- Average True Range (ATR)
- ROIV 0.47
- CWAN 0.53
- MACD
- ROIV 0.22
- CWAN -0.09
- Stochastic Oscillator
- ROIV 81.67
- CWAN 7.61
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.